Strategies to enhance the therapeutic efficacy of autologous hematopoietic stem cell transplantation by posttransplantation adoptive transfer of T cells with engineered graft-versus-tumor activity

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 2 SUPPL. 2, 2005, Pages 34-39

  Jensen, Michael ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Adoptive therapy; Chimeric immunoreceptor; Leukemia

Indexed keywords

FC RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER; CANCER IMMUNOTHERAPY; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; IMMUNOREGULATION; LYMPHOCYTE CLONE; NASOPHARYNX CARCINOMA; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VACCINATION;

GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; THERAPEUTIC EQUIVALENCY; TRANSPLANTATION, AUTOLOGOUS;

EID: 13244262613     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.11.012     Document Type: Article

References (61)

1. K.M. Sullivan A. Fefer R. Witherspoon et al. Graft-versus-leukemia in man: Relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation Prog Clin Biol Res. 244 1987 391-399
2. A. Fefer K.M. Sullivan P. Weiden et al. Graft versus leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation Prog Clin Biol Res. 244 1987 401-408
3. R.P. Gale M.M. Horowitz R.C. Ash et al. Identical-twin bone marrow transplants for leukemia Ann Intern Med. 120 1994 646-652
4. J. Barrett R. Childs New directions in allogeneic stem cell transplantation Semin Hematol. 39 2002 1-2
5. R. Childs A. Chernoff N. Contentin et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation N Engl J Med. 343 2000 750-758
6. D. Drachenberg R.W. Childs Allogeneic hematopoietic stem cell transplantation for cytokine refractory renal cell carcinoma Cancer Treat Res. 116 2003 213-226
7. R. Childs R. Srinivasan Advances in allogeneic stem cell transplantation: Directing graft-versus-leukemia at solid tumors Cancer J. 8 2002 2-11
8. C. Perreault R. Belanger Y. Bonny M. Gyger D.C. Roy Critical issues in bone marrow transplantation immunology Bone Marrow Transplant. 7 suppl 1 1991 24-25
9. R.L. Truitt A.A. Atasoylu Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow Bone Marrow Transplant. 8 1991 51-58
10. S. Pion P. Fontaine C. Baron M. Gyger C. Perreault Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy J Clin Invest. 95 1995 1561-1568
11. H.J. Kolb A. Schattenberg J.M. Goldman et al. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 86 1995 2041-2050
12. B.M. Bar A. Schattenberg E.J. Mensink et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation J Clin Oncol. 11 1993 513-519
13. E.H. Warren M. Gavin P.D. Greenberg S.R. Riddell Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation Curr Opin Hematol. 5 1998 429-433
14. S.R. Riddell C. Berger M. Murata S. Randolph E.H. Warren The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation Blood Rev. 17 2003 153-162
15. E.H. Warren P.D. Greenberg S.R. Riddell Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution Blood 91 1998 2197-2207
16. E.A. Walter P.D. Greenberg M.J. Gilbert et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor N Engl J Med. 333 1995 1038-1044
17. H.E. Heslop C.Y. Ng C. Li et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes Nat Med. 2 1996 551-555
18. S.R. Riddell K.S. Watanabe J.M. Goodrich et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones Science 257 1992 238-241
19. C.M. Bollard B. Savoldo C.M. Rooney H.E. Heslop Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease Acta Haematol. 110 2003 139-148
20. C.M. Rooney L.K. Aguilar M.H. Huls M.K. Brenner H.E. Heslop Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines Curr Top Microbiol Immunol. 258 2001 221-229
21. M.A. Roskrow N. Suzuki Y. Gan et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease Blood 91 1998 2925-2934
22. M.H. Huls C.M. Rooney H.E. Heslop Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease Acta Haematol. 110 2003 149-153
23. J.J. Mule S. Shu S.L. Schwarz S.A. Rosenberg Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2 Science 225 1984 1487-1489
24. M.T. Lotze S.A. Rosenberg Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer Immunobiology 172 1986 420-437
25. S.A. Rosenberg M.T. Lotze L.M. Muul et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N Engl J Med. 316 1987 889-897
26. S.A. Rosenberg M.T. Lotze J.C. Yang et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer J Natl Cancer Inst. 85 1993 622-632
27. B. Fisher B.S. Packard E.J. Read et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma J Clin Oncol. 7 1989 250-261
28. J.R. Yannelli C. Hyatt S. McConnell et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience Int J Cancer 65 1996 413-421
29. T. Boon P. Coulie M. Marchand et al. Genes coding for tumor rejection antigens: Perspectives for specific immunotherapy Important Adv Oncol. 1994 53-69
30. Y.T. Chen Cancer vaccine: Identification of human tumor antigens by SEREX Cancer J. 6 suppl 3 2000 S208-S217
31. N. Renkvist C. Castelli P.F. Robbins G. Parmiani A listing of human tumor antigens recognized by T cells Cancer Immunol Immunother. 50 2001 3-15
32. T.M. Clay M.C. Custer J. Sachs et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity J Immunol. 163 1999 507-513
33. L.J. Cooper M. Kalos D.A. Lewinsohn S.R. Riddell P.D. Greenberg Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes J Virol. 74 2000 8207-8212
34. T. Stanislawski R.H. Voss C. Lotz et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer Nat Immunol. 2 2001 962-970
35. R.A. Willemsen M.E. Weijtens C. Ronteltap et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR Gene Ther. 7 2000 1369-1377
36. T.M. Clay M. Morse H.K. Lyerly Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes Expert Opin Biol Ther. 2 2002 353-360
37. R. Debets R. Willemsen R. Bolhuis Adoptive transfer of T-cell immunity: gene transfer with MHC-restricted receptors Trends Immunol. 23 2002 435-436
38. A. Weiss Molecular and genetic insights into T cell antigen receptor structure and function Annu Rev Genet. 25 1991 487-510
39. B.A. Irving A. Weiss The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways Cell 64 1991 891-901
40. A.C. Chan B.A. Irving J.D. Fraser A. Weiss The zeta chain is associated with a tyrosine kinase and upon T-cell antigen receptor stimulation associates with ZAP-70, a 70-kDa tyrosine phosphoprotein Proc Natl Acad Sci U S A 88 1991 9166-9170
41. R.E. Bird K.D. Hardman J.W. Jacobson et al. Single-chain antigen-binding proteins Science 242 1988 423-426
42. Z. Eshhar T. Waks G. Gross D.G. Schindler Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors Proc Natl Acad Sci U S A 90 1993 720-724
43. T. Brocker A. Peter A. Traunecker K. Karjalainen New simplified molecular design for functional T cell receptor Eur J Immunol. 23 1993 1435-1439
44. U. Altenschmidt E. Klundt B. Groner Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression J Immunol. 159 1997 5509-5515
45. A. Hekele P. Dall D. Moritz et al. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zEta-chimera Int J Cancer 68 1996 232-238
46. R.J. Brentjens J.B. Latouche E. Santos et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 Nat Med. 9 2003 279-286
47. M.C. Jensen Targeting malignant B cells of lymphoma and leukemia with genetically engineered T-cell clones Cytotherapy 4 2002 443-444
48. L.J. Cooper M.S. Topp L.M. Serrano et al. T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect Blood 101 2003 1637-1644
49. D.C. Thomis S. Marktel C. Bonini et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease Blood 97 2001 1249-1257
50. K. Junker U. Koehl S. Zimmerman et al. Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes Gene Ther. 10 2003 1189-1197
51. W. Qasim A.J. Thrasher J. Buddle et al. T cell transduction and suicide with an enhanced mutant thymidine kinase Gene Ther. 9 2002 824-827
52. K.C. Straathof D.M. Spencer R.E. Sutton C.M. Rooney Suicide genes as safety switches in T lymphocytes Cytotherapy 5 2003 227-230
53. C.L. Mackall F.T. Hakim R.E. Gress Restoration of T-cell homeostasis after T-cell depletion Semin Immunol. 9 1997 339-346
54. C.L. Mackall C.V. Bare L.A. Granger et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing J Immunol. 156 1996 4609-4616
55. M. Correia-Neves C. Waltzinger D. Mathis C. Benoist The shaping of the T cell repertoire Immunity 14 2001 21-32
56. T.J. Eberlein M. Rosenstein S.A. Rosenberg Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2 J Exp Med. 156 1982 385-397
57. G.N. Maine J.J. Mule Making room for T cells J Clin Invest. 110 2002 157-159
58. W. Dummer A.G. Niethammer R. Baccala et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity J Clin Invest. 110 2002 185-192
59. C. Rossig C.M. Bollard J.G. Nuchtern C.M. Rooney M.K. Brenner Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: Potential for improved immunotherapy Blood 99 2002 2009-2016
60. M.H. Kershaw J.A. Westwood P. Hwu Dual-specific T cells combine proliferation and antitumor activity Nat Biotechnol. 20 2002 1221-1227
61. C. Berger M.L. Huang M. Gough et al. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model J Virol. 75 2001 799-808